| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medical Oncology | 19 | 2019 | 2265 | 2.470 |
Why?
|
| Neoplasms | 41 | 2018 | 21683 | 1.110 |
Why?
|
| Health Care Costs | 9 | 2019 | 3209 | 0.900 |
Why?
|
| Societies, Medical | 9 | 2017 | 3743 | 0.860 |
Why?
|
| Antineoplastic Agents | 20 | 2018 | 13695 | 0.660 |
Why?
|
| Cost Savings | 3 | 2019 | 926 | 0.620 |
Why?
|
| Alphapapillomavirus | 1 | 2020 | 221 | 0.600 |
Why?
|
| Simplexvirus | 20 | 1987 | 802 | 0.600 |
Why?
|
| Famous Persons | 1 | 2018 | 108 | 0.580 |
Why?
|
| Continuity of Patient Care | 2 | 2014 | 1049 | 0.560 |
Why?
|
| DNA Topoisomerases, Type II | 5 | 1997 | 121 | 0.520 |
Why?
|
| Delivery of Health Care | 6 | 2019 | 5319 | 0.480 |
Why?
|
| Bone Marrow Transplantation | 16 | 1998 | 2765 | 0.430 |
Why?
|
| Diphosphonates | 1 | 2017 | 623 | 0.410 |
Why?
|
| Drug Costs | 3 | 2016 | 1105 | 0.380 |
Why?
|
| Costs and Cost Analysis | 2 | 2016 | 1681 | 0.380 |
Why?
|
| Choice Behavior | 1 | 2016 | 803 | 0.360 |
Why?
|
| Medicare Part D | 1 | 2014 | 328 | 0.360 |
Why?
|
| Fee-for-Service Plans | 1 | 2014 | 694 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 30 | 2013 | 11524 | 0.320 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 1587 | 0.320 |
Why?
|
| Drug Utilization | 1 | 2014 | 1183 | 0.320 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 3479 | 0.320 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 2020 | 0.310 |
Why?
|
| Prescription Drugs | 1 | 2014 | 595 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 3 | 2013 | 7279 | 0.290 |
Why?
|
| Advisory Committees | 3 | 2017 | 775 | 0.290 |
Why?
|
| Patient Participation | 1 | 2016 | 1457 | 0.290 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 1956 | 0.270 |
Why?
|
| Health Care Reform | 1 | 2014 | 1261 | 0.260 |
Why?
|
| Etoposide | 7 | 1998 | 641 | 0.250 |
Why?
|
| United States | 20 | 2018 | 69872 | 0.240 |
Why?
|
| Alkylating Agents | 6 | 1993 | 139 | 0.230 |
Why?
|
| Kanamycin Kinase | 3 | 1998 | 34 | 0.220 |
Why?
|
| Immunotherapy | 1 | 2018 | 4445 | 0.210 |
Why?
|
| Cytarabine | 4 | 1986 | 692 | 0.210 |
Why?
|
| Clinical Trials as Topic | 8 | 2014 | 7913 | 0.210 |
Why?
|
| Health Policy | 1 | 2014 | 2661 | 0.210 |
Why?
|
| Acyclovir | 10 | 1989 | 272 | 0.200 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2001 | 82 | 0.200 |
Why?
|
| DNA, Viral | 10 | 1987 | 2225 | 0.200 |
Why?
|
| Medicaid | 1 | 2014 | 2736 | 0.200 |
Why?
|
| Novobiocin | 3 | 1991 | 35 | 0.190 |
Why?
|
| Immunotoxins | 1 | 2001 | 179 | 0.190 |
Why?
|
| Zimbabwe | 1 | 2020 | 129 | 0.180 |
Why?
|
| Humans | 103 | 2020 | 744343 | 0.180 |
Why?
|
| Gene Rearrangement | 3 | 2000 | 1179 | 0.180 |
Why?
|
| Adenovirus E1A Proteins | 2 | 2000 | 76 | 0.180 |
Why?
|
| Drug Industry | 3 | 2018 | 746 | 0.170 |
Why?
|
| United States Food and Drug Administration | 2 | 2018 | 1584 | 0.170 |
Why?
|
| Breast Neoplasms | 14 | 2017 | 20822 | 0.170 |
Why?
|
| Adenoviridae | 5 | 1998 | 1099 | 0.160 |
Why?
|
| Cisplatin | 10 | 1995 | 1662 | 0.160 |
Why?
|
| Drug Resistance | 6 | 1996 | 1609 | 0.150 |
Why?
|
| Restriction Mapping | 5 | 1997 | 878 | 0.150 |
Why?
|
| Bromodeoxyuridine | 4 | 1987 | 322 | 0.150 |
Why?
|
| Hodgkin Disease | 4 | 1997 | 1415 | 0.140 |
Why?
|
| Guanine | 8 | 1982 | 274 | 0.140 |
Why?
|
| Capacity Building | 1 | 2019 | 248 | 0.140 |
Why?
|
| Pentosyltransferases | 1 | 1996 | 65 | 0.140 |
Why?
|
| Drug Evaluation | 13 | 1992 | 647 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 5 | 2019 | 5391 | 0.140 |
Why?
|
| Colony-Stimulating Factors | 4 | 1989 | 221 | 0.140 |
Why?
|
| Combined Modality Therapy | 19 | 2012 | 8642 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2014 | 841 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 15076 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 6773 | 0.120 |
Why?
|
| Lung Neoplasms | 6 | 2014 | 13102 | 0.120 |
Why?
|
| Cyclophosphamide | 16 | 1997 | 2242 | 0.120 |
Why?
|
| Cricetinae | 8 | 1995 | 2472 | 0.120 |
Why?
|
| Growth Substances | 4 | 1989 | 784 | 0.120 |
Why?
|
| Oncology Service, Hospital | 1 | 2014 | 57 | 0.120 |
Why?
|
| DNA Replication | 5 | 1995 | 1399 | 0.120 |
Why?
|
| Mycophenolic Acid | 1 | 1996 | 343 | 0.120 |
Why?
|
| Cost of Illness | 2 | 2016 | 1859 | 0.120 |
Why?
|
| Phosphotransferases | 2 | 1992 | 308 | 0.110 |
Why?
|
| Vidarabine | 3 | 1984 | 345 | 0.110 |
Why?
|
| Diphtheria Toxin | 1 | 1994 | 255 | 0.110 |
Why?
|
| Cell Transformation, Viral | 4 | 1983 | 565 | 0.110 |
Why?
|
| Cloning, Molecular | 3 | 2000 | 4320 | 0.110 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 1990 | 87 | 0.110 |
Why?
|
| Antineoplastic Protocols | 1 | 2012 | 50 | 0.110 |
Why?
|
| Guideline Adherence | 2 | 2013 | 2266 | 0.100 |
Why?
|
| Carmustine | 8 | 1997 | 137 | 0.100 |
Why?
|
| Kallikreins | 1 | 2013 | 258 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2014 | 629 | 0.100 |
Why?
|
| Antiemetics | 1 | 2013 | 177 | 0.100 |
Why?
|
| Transfection | 6 | 1998 | 5892 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1995 | 627 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 1999 | 5442 | 0.100 |
Why?
|
| Carboplatin | 12 | 1998 | 801 | 0.100 |
Why?
|
| DNA | 6 | 1995 | 7301 | 0.090 |
Why?
|
| Remission Induction | 10 | 1998 | 2386 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2017 | 1205 | 0.090 |
Why?
|
| Podophyllotoxin | 1 | 1990 | 21 | 0.090 |
Why?
|
| Suicide, Assisted | 3 | 2001 | 64 | 0.090 |
Why?
|
| Phosphonoacetic Acid | 5 | 1983 | 55 | 0.090 |
Why?
|
| 3T3 Cells | 3 | 1998 | 1101 | 0.090 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 432 | 0.090 |
Why?
|
| Ultraviolet Rays | 5 | 1989 | 1060 | 0.090 |
Why?
|
| Stomatitis, Herpetic | 1 | 1989 | 12 | 0.090 |
Why?
|
| Female | 47 | 2020 | 380194 | 0.090 |
Why?
|
| Transplantation, Autologous | 12 | 1998 | 2124 | 0.090 |
Why?
|
| Prevalence | 2 | 2020 | 15226 | 0.090 |
Why?
|
| Immunologic Factors | 2 | 2018 | 1580 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 3 | 1995 | 3772 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 1439 | 0.080 |
Why?
|
| Cell Division | 5 | 1998 | 4568 | 0.080 |
Why?
|
| Professional Practice | 1 | 2010 | 326 | 0.080 |
Why?
|
| CHO Cells | 4 | 1995 | 1406 | 0.080 |
Why?
|
| Information Dissemination | 1 | 2016 | 1099 | 0.080 |
Why?
|
| Leukopenia | 1 | 1988 | 212 | 0.080 |
Why?
|
| Oncogenes | 2 | 1992 | 1265 | 0.080 |
Why?
|
| Health Services Accessibility | 3 | 2019 | 5137 | 0.080 |
Why?
|
| Leadership | 1 | 2017 | 1357 | 0.080 |
Why?
|
| Ovary | 2 | 1990 | 981 | 0.080 |
Why?
|
| Thymidine Kinase | 5 | 1983 | 290 | 0.080 |
Why?
|
| Bloom Syndrome | 1 | 1987 | 8 | 0.080 |
Why?
|
| Health Priorities | 1 | 2010 | 380 | 0.080 |
Why?
|
| Point Mutation | 1 | 1993 | 1623 | 0.070 |
Why?
|
| Recombination, Genetic | 4 | 1992 | 1586 | 0.070 |
Why?
|
| Tumor Virus Infections | 1 | 1990 | 452 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2012 | 1184 | 0.070 |
Why?
|
| Interleukin-2 | 1 | 1994 | 1904 | 0.070 |
Why?
|
| Blotting, Southern | 3 | 1993 | 803 | 0.070 |
Why?
|
| Physician-Patient Relations | 2 | 2010 | 3229 | 0.070 |
Why?
|
| DNA Repair | 2 | 1987 | 2046 | 0.070 |
Why?
|
| Hospitals | 1 | 2020 | 3952 | 0.070 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 3843 | 0.070 |
Why?
|
| Gentamicins | 2 | 1998 | 255 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 3086 | 0.070 |
Why?
|
| Drug Resistance, Microbial | 7 | 1984 | 862 | 0.070 |
Why?
|
| Antiviral Agents | 7 | 1984 | 2987 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2017 | 2575 | 0.070 |
Why?
|
| Euthanasia | 3 | 2001 | 51 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 3923 | 0.070 |
Why?
|
| Cell Line | 14 | 2000 | 15997 | 0.070 |
Why?
|
| Genes, Viral | 5 | 1987 | 718 | 0.070 |
Why?
|
| Thiotepa | 6 | 1996 | 66 | 0.060 |
Why?
|
| Virus Replication | 5 | 1986 | 2534 | 0.060 |
Why?
|
| DNA-Directed DNA Polymerase | 5 | 1984 | 486 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2013 | 2727 | 0.060 |
Why?
|
| Organizational Objectives | 1 | 2006 | 438 | 0.060 |
Why?
|
| Male | 40 | 2019 | 350118 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2012 | 1167 | 0.060 |
Why?
|
| Treatment Outcome | 11 | 2019 | 63114 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 9274 | 0.060 |
Why?
|
| Burkitt Lymphoma | 2 | 1990 | 327 | 0.060 |
Why?
|
| Transcription, Genetic | 5 | 1997 | 7722 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 2 | 1999 | 420 | 0.060 |
Why?
|
| Bone Marrow | 3 | 1989 | 2948 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 3158 | 0.060 |
Why?
|
| Hematoporphyrins | 2 | 1980 | 23 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 2494 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 1998 | 1526 | 0.060 |
Why?
|
| Sulfasalazine | 1 | 2003 | 79 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 2212 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2016 | 23338 | 0.060 |
Why?
|
| Base Sequence | 7 | 2000 | 12797 | 0.060 |
Why?
|
| Plasminogen | 1 | 2003 | 152 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 1994 | 903 | 0.050 |
Why?
|
| Lymphocytosis | 1 | 2003 | 119 | 0.050 |
Why?
|
| Ifosfamide | 5 | 1998 | 228 | 0.050 |
Why?
|
| Plasminogen Activators | 1 | 2003 | 209 | 0.050 |
Why?
|
| Methylene Blue | 2 | 1980 | 155 | 0.050 |
Why?
|
| Forecasting | 2 | 2010 | 2951 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2003 | 2038 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1990 | 1381 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 1998 | 10943 | 0.050 |
Why?
|
| Captopril | 1 | 2003 | 272 | 0.050 |
Why?
|
| Keratins | 1 | 1984 | 515 | 0.050 |
Why?
|
| Electricity | 2 | 1980 | 182 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 1983 | 215 | 0.050 |
Why?
|
| Isoenzymes | 2 | 1997 | 1726 | 0.050 |
Why?
|
| Drug Administration Schedule | 6 | 1994 | 4933 | 0.050 |
Why?
|
| Simian virus 40 | 4 | 1976 | 295 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 1989 | 1180 | 0.050 |
Why?
|
| Herpes Labialis | 4 | 1984 | 29 | 0.050 |
Why?
|
| Clone Cells | 3 | 1996 | 1692 | 0.050 |
Why?
|
| Liver Failure | 1 | 2003 | 241 | 0.050 |
Why?
|
| Patient Selection | 1 | 2013 | 4215 | 0.050 |
Why?
|
| Exotoxins | 1 | 2001 | 119 | 0.050 |
Why?
|
| Quality Improvement | 2 | 2017 | 3749 | 0.050 |
Why?
|
| Pseudomonas | 1 | 2001 | 117 | 0.050 |
Why?
|
| Euthanasia, Active, Voluntary | 1 | 2000 | 11 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 2 | 1990 | 1041 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2007 | 1683 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 776 | 0.050 |
Why?
|
| Molecular Sequence Data | 5 | 2000 | 18111 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 1995 | 5172 | 0.050 |
Why?
|
| Epidermis | 1 | 1984 | 528 | 0.050 |
Why?
|
| Animals | 27 | 2003 | 168757 | 0.050 |
Why?
|
| Infectious Mononucleosis | 1 | 1981 | 131 | 0.050 |
Why?
|
| Gene Expression | 3 | 1998 | 7799 | 0.050 |
Why?
|
| Peptide Fragments | 2 | 2003 | 5097 | 0.050 |
Why?
|
| Interferons | 1 | 1984 | 706 | 0.050 |
Why?
|
| Mutation | 10 | 1998 | 29786 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2003 | 591 | 0.040 |
Why?
|
| Plasma | 2 | 2003 | 575 | 0.040 |
Why?
|
| Survival Rate | 8 | 2003 | 12788 | 0.040 |
Why?
|
| Enterotoxins | 1 | 2001 | 368 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2000 | 374 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1997 | 1085 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 25043 | 0.040 |
Why?
|
| Light | 3 | 1980 | 1374 | 0.040 |
Why?
|
| Infusions, Intravenous | 5 | 2002 | 2274 | 0.040 |
Why?
|
| Cell Survival | 5 | 1993 | 5882 | 0.040 |
Why?
|
| Herpes Simplex | 1 | 1982 | 470 | 0.040 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2005 | 643 | 0.040 |
Why?
|
| Hematologic Diseases | 2 | 1994 | 498 | 0.040 |
Why?
|
| Mesna | 3 | 1998 | 66 | 0.040 |
Why?
|
| Phorbol Esters | 2 | 1989 | 111 | 0.040 |
Why?
|
| Quality of Life | 2 | 2018 | 12804 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 1998 | 1783 | 0.040 |
Why?
|
| Middle Aged | 36 | 2005 | 213383 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 1986 | 1376 | 0.040 |
Why?
|
| Mice | 12 | 2003 | 81183 | 0.040 |
Why?
|
| Adult | 39 | 2005 | 214055 | 0.040 |
Why?
|
| Physicians | 2 | 2012 | 4567 | 0.040 |
Why?
|
| Genetic Complementation Test | 1 | 1998 | 562 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2009 | 1901 | 0.040 |
Why?
|
| Prostatic Neoplasms | 3 | 2019 | 11124 | 0.040 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 1995 | 501 | 0.040 |
Why?
|
| Base Composition | 1 | 1997 | 293 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 3507 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 6234 | 0.040 |
Why?
|
| South America | 1 | 2017 | 181 | 0.040 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2003 | 570 | 0.040 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 2 | 1995 | 222 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 7785 | 0.040 |
Why?
|
| Collagen | 2 | 2003 | 2689 | 0.040 |
Why?
|
| Africa | 1 | 2019 | 673 | 0.040 |
Why?
|
| Ribonucleases | 1 | 1997 | 287 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 1998 | 648 | 0.040 |
Why?
|
| Granulocytes | 2 | 1989 | 548 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2009 | 2494 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 14722 | 0.040 |
Why?
|
| Cricetulus | 2 | 1990 | 816 | 0.040 |
Why?
|
| Hygromycin B | 1 | 1996 | 11 | 0.040 |
Why?
|
| Puromycin | 1 | 1996 | 44 | 0.040 |
Why?
|
| Fibrosarcoma | 3 | 1989 | 348 | 0.040 |
Why?
|
| Risk Factors | 4 | 2019 | 72290 | 0.040 |
Why?
|
| Cell Size | 1 | 1998 | 643 | 0.040 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1998 | 264 | 0.030 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1996 | 192 | 0.030 |
Why?
|
| Leukocyte Count | 4 | 2003 | 1588 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 1996 | 80 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1992 | 8428 | 0.030 |
Why?
|
| Jurisprudence | 1 | 1996 | 110 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 9959 | 0.030 |
Why?
|
| Social Control, Formal | 1 | 1996 | 110 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 1992 | 2942 | 0.030 |
Why?
|
| Minority Groups | 1 | 2003 | 1223 | 0.030 |
Why?
|
| Communication | 1 | 2009 | 3749 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 1997 | 5867 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2000 | 859 | 0.030 |
Why?
|
| Urogenital Neoplasms | 1 | 1976 | 137 | 0.030 |
Why?
|
| Drug Hypersensitivity | 1 | 2003 | 884 | 0.030 |
Why?
|
| Neoplasm Metastasis | 6 | 1996 | 4851 | 0.030 |
Why?
|
| Kinetics | 4 | 1993 | 6473 | 0.030 |
Why?
|
| Bone Marrow Diseases | 2 | 1994 | 231 | 0.030 |
Why?
|
| Drug Synergism | 2 | 1990 | 1792 | 0.030 |
Why?
|
| Sarcoma | 4 | 1995 | 1897 | 0.030 |
Why?
|
| Disease-Free Survival | 5 | 2010 | 6895 | 0.030 |
Why?
|
| RNA Splicing | 1 | 1998 | 907 | 0.030 |
Why?
|
| Quality of Health Care | 2 | 2017 | 4371 | 0.030 |
Why?
|
| Organoplatinum Compounds | 3 | 1990 | 408 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 681 | 0.030 |
Why?
|
| Camptothecin | 1 | 1996 | 576 | 0.030 |
Why?
|
| Transformation, Genetic | 1 | 1993 | 192 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 1978 | 1074 | 0.030 |
Why?
|
| Survival Analysis | 5 | 2007 | 10252 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2000 | 12072 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 1991 | 5221 | 0.030 |
Why?
|
| Antibodies | 1 | 2001 | 2460 | 0.030 |
Why?
|
| State Government | 1 | 1996 | 372 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1995 | 520 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2000 | 2751 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2003 | 2635 | 0.030 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1993 | 134 | 0.030 |
Why?
|
| Mice, Inbred C3H | 2 | 1991 | 964 | 0.030 |
Why?
|
| Recombinant Proteins | 4 | 2003 | 6622 | 0.030 |
Why?
|
| Testicular Neoplasms | 2 | 1995 | 804 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 1998 | 13033 | 0.030 |
Why?
|
| Creatinine | 2 | 2002 | 1919 | 0.030 |
Why?
|
| Melphalan | 4 | 1996 | 431 | 0.020 |
Why?
|
| HeLa Cells | 1 | 1997 | 3128 | 0.020 |
Why?
|
| Government Regulation | 1 | 1996 | 522 | 0.020 |
Why?
|
| DNA Primers | 1 | 1995 | 2892 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1993 | 1581 | 0.020 |
Why?
|
| Sarcoma, Experimental | 1 | 1991 | 128 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1995 | 1213 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20129 | 0.020 |
Why?
|
| Time Factors | 12 | 2018 | 40075 | 0.020 |
Why?
|
| Adenocarcinoma | 2 | 1993 | 6364 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2007 | 5256 | 0.020 |
Why?
|
| Retroviridae Infections | 1 | 1990 | 151 | 0.020 |
Why?
|
| Fluorouracil | 2 | 1993 | 1619 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1997 | 1988 | 0.020 |
Why?
|
| Superoxides | 2 | 1989 | 387 | 0.020 |
Why?
|
| Mastectomy | 1 | 1998 | 1793 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 2 | 1997 | 4803 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 2 | 1998 | 7181 | 0.020 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 1989 | 258 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 9438 | 0.020 |
Why?
|
| Insurance, Hospitalization | 1 | 1988 | 30 | 0.020 |
Why?
|
| Terminal Care | 1 | 2001 | 1694 | 0.020 |
Why?
|
| Methotrexate | 3 | 1993 | 1727 | 0.020 |
Why?
|
| Leukemia | 1 | 1996 | 1511 | 0.020 |
Why?
|
| Immune System | 1 | 1994 | 805 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 2 | 1993 | 3386 | 0.020 |
Why?
|
| Palliative Care | 2 | 2001 | 3493 | 0.020 |
Why?
|
| Genes | 2 | 1984 | 1893 | 0.020 |
Why?
|
| AIDS-Related Complex | 1 | 1987 | 110 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2003 | 3309 | 0.020 |
Why?
|
| Leukemia L1210 | 1 | 1987 | 45 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1995 | 6314 | 0.020 |
Why?
|
| Ribonucleosides | 1 | 1987 | 82 | 0.020 |
Why?
|
| Disease Management | 1 | 2018 | 2459 | 0.020 |
Why?
|
| Leukemia, Myeloid | 2 | 1986 | 707 | 0.020 |
Why?
|
| Neutropenia | 2 | 1993 | 895 | 0.020 |
Why?
|
| Mutagenicity Tests | 1 | 1986 | 46 | 0.020 |
Why?
|
| Kidney | 5 | 1984 | 7186 | 0.020 |
Why?
|
| Aged | 14 | 2005 | 163280 | 0.020 |
Why?
|
| Biomedical Technology | 1 | 2009 | 220 | 0.020 |
Why?
|
| Vero Cells | 1 | 1987 | 485 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 1989 | 434 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2019 | 2348 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 1986 | 356 | 0.020 |
Why?
|
| Dexamethasone | 1 | 1993 | 1951 | 0.020 |
Why?
|
| Mortality | 1 | 1997 | 2864 | 0.020 |
Why?
|
| Philadelphia Chromosome | 1 | 1986 | 112 | 0.020 |
Why?
|
| Mutagens | 1 | 1986 | 168 | 0.020 |
Why?
|
| Cells, Cultured | 4 | 1990 | 19229 | 0.020 |
Why?
|
| DNA Damage | 1 | 1995 | 2432 | 0.020 |
Why?
|
| Platelet Count | 1 | 1988 | 781 | 0.020 |
Why?
|
| Ribavirin | 1 | 1987 | 395 | 0.020 |
Why?
|
| Hybridization, Genetic | 3 | 1975 | 109 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1988 | 927 | 0.020 |
Why?
|
| Tritium | 2 | 1984 | 745 | 0.020 |
Why?
|
| Health Personnel | 1 | 2018 | 3218 | 0.020 |
Why?
|
| Placebos | 3 | 2003 | 1676 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 1988 | 397 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 2429 | 0.020 |
Why?
|
| Hepatitis B | 1 | 1990 | 695 | 0.020 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1984 | 104 | 0.020 |
Why?
|
| Salmonella typhimurium | 1 | 1986 | 351 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1988 | 1663 | 0.010 |
Why?
|
| Morals | 1 | 2006 | 284 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 1988 | 705 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 1990 | 1119 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 840 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1996 | 4217 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2000 | 2214 | 0.010 |
Why?
|
| Angiostatins | 1 | 2003 | 67 | 0.010 |
Why?
|
| Chromatography | 1 | 2003 | 206 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2007 | 826 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 6171 | 0.010 |
Why?
|
| Economics, Pharmaceutical | 1 | 2003 | 87 | 0.010 |
Why?
|
| Antigens, Viral | 4 | 1981 | 1035 | 0.010 |
Why?
|
| Karyotyping | 1 | 2005 | 1243 | 0.010 |
Why?
|
| Photochemistry | 2 | 1980 | 238 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 1997 | 5853 | 0.010 |
Why?
|
| Adolescent | 11 | 2001 | 85781 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 829 | 0.010 |
Why?
|
| Liver Neoplasms | 3 | 2000 | 4253 | 0.010 |
Why?
|
| Endostatins | 1 | 2002 | 174 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1993 | 8436 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2003 | 387 | 0.010 |
Why?
|
| Purine Nucleotides | 1 | 1981 | 28 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1986 | 1063 | 0.010 |
Why?
|
| Interferon Type I | 1 | 1985 | 542 | 0.010 |
Why?
|
| Mesocricetus | 1 | 1981 | 252 | 0.010 |
Why?
|
| Laminin | 1 | 2003 | 419 | 0.010 |
Why?
|
| Serotonin | 3 | 1970 | 1017 | 0.010 |
Why?
|
| Quinazolines | 1 | 2007 | 1356 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 772 | 0.010 |
Why?
|
| Binding Sites | 1 | 1990 | 6114 | 0.010 |
Why?
|
| Incidence | 1 | 2019 | 20947 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1986 | 1276 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1986 | 1758 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 19905 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 1801 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1997 | 9648 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1991 | 1622 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2002 | 599 | 0.010 |
Why?
|
| Financing, Government | 1 | 2003 | 468 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 694 | 0.010 |
Why?
|
| Arabinonucleotides | 1 | 1979 | 5 | 0.010 |
Why?
|
| Vidarabine Phosphate | 1 | 1979 | 11 | 0.010 |
Why?
|
| Drug Therapy, Combination | 3 | 1991 | 6489 | 0.010 |
Why?
|
| Pain, Intractable | 1 | 2000 | 130 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2003 | 835 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1991 | 2149 | 0.010 |
Why?
|
| Lymphokines | 1 | 2002 | 949 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 2278 | 0.010 |
Why?
|
| Doxorubicin | 2 | 1998 | 2234 | 0.010 |
Why?
|
| Physical Examination | 1 | 2005 | 1237 | 0.010 |
Why?
|
| Etanidazole | 1 | 1998 | 26 | 0.010 |
Why?
|
| Expectorants | 1 | 1998 | 16 | 0.010 |
Why?
|
| Syndrome | 1 | 2005 | 3251 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1987 | 2232 | 0.010 |
Why?
|
| Herpesviridae | 1 | 1979 | 109 | 0.010 |
Why?
|
| Neoplasm Staging | 3 | 1998 | 11031 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2003 | 1677 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2002 | 2327 | 0.010 |
Why?
|
| DNA, Single-Stranded | 1 | 1980 | 354 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1995 | 4838 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 1959 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 2 | 1989 | 380 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 3610 | 0.010 |
Why?
|
| Pedigree | 1 | 2005 | 4644 | 0.010 |
Why?
|
| X Chromosome | 1 | 1981 | 814 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 1989 | 12026 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2005 | 1788 | 0.010 |
Why?
|
| Prognosis | 4 | 1997 | 29063 | 0.010 |
Why?
|
| Dysgerminoma | 1 | 1976 | 65 | 0.010 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1996 | 102 | 0.010 |
Why?
|
| Salvage Therapy | 2 | 1994 | 1275 | 0.010 |
Why?
|
| Vinca Alkaloids | 1 | 1976 | 35 | 0.010 |
Why?
|
| Euthanasia, Active | 1 | 1996 | 15 | 0.010 |
Why?
|
| Conscience | 1 | 1996 | 6 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1987 | 4161 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3920 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4186 | 0.010 |
Why?
|
| Leiomyosarcoma | 1 | 2000 | 477 | 0.010 |
Why?
|
| Morphine | 1 | 2000 | 657 | 0.010 |
Why?
|
| Right to Die | 1 | 1996 | 32 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 2839 | 0.010 |
Why?
|
| Antimetabolites | 1 | 1976 | 125 | 0.010 |
Why?
|
| Freedom | 1 | 1996 | 69 | 0.010 |
Why?
|
| DNA Footprinting | 1 | 1995 | 98 | 0.010 |
Why?
|
| Oregon | 1 | 1996 | 140 | 0.010 |
Why?
|
| Coercion | 1 | 1996 | 63 | 0.010 |
Why?
|
| Genomic Library | 1 | 1995 | 193 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1998 | 675 | 0.010 |
Why?
|
| Canada | 1 | 2001 | 2065 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1979 | 934 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2003 | 1678 | 0.010 |
Why?
|
| Recurrence | 4 | 1998 | 8340 | 0.010 |
Why?
|
| Mentally Ill Persons | 1 | 1996 | 126 | 0.010 |
Why?
|
| Penile Neoplasms | 1 | 1976 | 160 | 0.010 |
Why?
|
| Mandatory Reporting | 1 | 1996 | 121 | 0.010 |
Why?
|
| Mental Competency | 1 | 1996 | 176 | 0.010 |
Why?
|
| Decision Making | 2 | 2001 | 3887 | 0.010 |
Why?
|
| Liability, Legal | 1 | 1996 | 213 | 0.010 |
Why?
|
| Digestive System | 1 | 1995 | 253 | 0.010 |
Why?
|
| Lung | 1 | 1992 | 9856 | 0.010 |
Why?
|
| Terminally Ill | 1 | 1996 | 238 | 0.010 |
Why?
|
| Personal Autonomy | 1 | 1996 | 298 | 0.010 |
Why?
|
| Privacy | 1 | 1996 | 239 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1982 | 2258 | 0.010 |
Why?
|
| Hypotension | 2 | 1970 | 884 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 2886 | 0.010 |
Why?
|
| Radiotherapy | 2 | 1998 | 1533 | 0.010 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1993 | 102 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1993 | 131 | 0.010 |
Why?
|
| Haplorhini | 1 | 1973 | 552 | 0.010 |
Why?
|
| Hydroxyindoleacetic Acid | 2 | 1970 | 90 | 0.010 |
Why?
|
| Proportional Hazards Models | 2 | 1999 | 12354 | 0.010 |
Why?
|
| Multivariate Analysis | 2 | 1997 | 12245 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1999 | 2879 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1976 | 692 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1995 | 1723 | 0.010 |
Why?
|
| Boston | 2 | 1996 | 9313 | 0.010 |
Why?
|
| Skin | 1 | 1985 | 4364 | 0.010 |
Why?
|
| Follow-Up Studies | 3 | 1991 | 39050 | 0.010 |
Why?
|
| Nervous System | 1 | 1995 | 554 | 0.010 |
Why?
|
| Aorta | 1 | 1979 | 2061 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1995 | 1547 | 0.010 |
Why?
|
| Administration, Topical | 2 | 1984 | 690 | 0.010 |
Why?
|
| Prejudice | 1 | 1996 | 570 | 0.010 |
Why?
|
| Confidentiality | 1 | 1996 | 612 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2002 | 3508 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 11366 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1993 | 323 | 0.010 |
Why?
|
| Species Specificity | 1 | 1995 | 2478 | 0.010 |
Why?
|
| Blood Cells | 1 | 1993 | 309 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1986 | 6544 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2000 | 6459 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 4456 | 0.010 |
Why?
|
| Comprehension | 1 | 1996 | 610 | 0.010 |
Why?
|
| Extracorporeal Circulation | 1 | 1970 | 182 | 0.010 |
Why?
|
| Melanoma | 1 | 1988 | 5510 | 0.010 |
Why?
|
| Breast | 1 | 1978 | 1969 | 0.010 |
Why?
|
| Phenotype | 1 | 1987 | 16365 | 0.010 |
Why?
|
| Informed Consent | 1 | 1996 | 995 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1989 | 222 | 0.010 |
Why?
|
| Patients | 1 | 1996 | 900 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2000 | 1832 | 0.010 |
Why?
|
| Hemorrhage | 2 | 1992 | 3461 | 0.010 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1972 | 547 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 13815 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 13284 | 0.000 |
Why?
|
| Bone Marrow Examination | 1 | 1988 | 157 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 12959 | 0.000 |
Why?
|
| Erythrocyte Count | 1 | 1988 | 163 | 0.000 |
Why?
|
| Pulmonary Fibrosis | 1 | 1992 | 530 | 0.000 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1989 | 821 | 0.000 |
Why?
|
| Methods | 1 | 1988 | 1129 | 0.000 |
Why?
|
| Erythroblasts | 1 | 1988 | 150 | 0.000 |
Why?
|
| Platinum | 1 | 1989 | 233 | 0.000 |
Why?
|
| Macrophage-1 Antigen | 1 | 1988 | 290 | 0.000 |
Why?
|
| Age Factors | 2 | 1995 | 18370 | 0.000 |
Why?
|
| Models, Biological | 1 | 1984 | 9583 | 0.000 |
Why?
|
| Microscopy, Electron | 2 | 1985 | 2645 | 0.000 |
Why?
|
| Flushing | 1 | 1986 | 49 | 0.000 |
Why?
|
| Pulse | 1 | 1986 | 229 | 0.000 |
Why?
|
| Hematocrit | 1 | 1987 | 636 | 0.000 |
Why?
|
| Pelvic Neoplasms | 1 | 1988 | 254 | 0.000 |
Why?
|
| Logistic Models | 1 | 2001 | 13408 | 0.000 |
Why?
|
| Half-Life | 1 | 1986 | 661 | 0.000 |
Why?
|
| Clinical Competence | 1 | 2001 | 4687 | 0.000 |
Why?
|
| Mathematics | 1 | 1986 | 728 | 0.000 |
Why?
|
| Neoplasm Transplantation | 1 | 1989 | 2085 | 0.000 |
Why?
|
| Aging | 1 | 1984 | 8664 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1989 | 53288 | 0.000 |
Why?
|
| Opportunistic Infections | 1 | 1987 | 389 | 0.000 |
Why?
|
| Analgesics, Opioid | 1 | 2000 | 3674 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1984 | 25625 | 0.000 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1976 | 2245 | 0.000 |
Why?
|
| Risk | 1 | 1996 | 9687 | 0.000 |
Why?
|
| Ganciclovir | 1 | 1984 | 258 | 0.000 |
Why?
|
| Protein Binding | 1 | 1995 | 9386 | 0.000 |
Why?
|
| Culture Media | 1 | 1985 | 908 | 0.000 |
Why?
|
| Feasibility Studies | 1 | 1993 | 5078 | 0.000 |
Why?
|
| Rabbits | 2 | 1979 | 4894 | 0.000 |
Why?
|
| Referral and Consultation | 1 | 1996 | 3528 | 0.000 |
Why?
|
| Cholera Toxin | 1 | 1985 | 556 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1986 | 1572 | 0.000 |
Why?
|
| Graft Survival | 1 | 1993 | 3737 | 0.000 |
Why?
|
| RNA, Viral | 3 | 1976 | 2902 | 0.000 |
Why?
|
| Remission, Spontaneous | 2 | 1972 | 382 | 0.000 |
Why?
|
| Lung Diseases | 1 | 1992 | 1886 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2005 | 23403 | 0.000 |
Why?
|
| Specimen Handling | 1 | 1986 | 694 | 0.000 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1988 | 1836 | 0.000 |
Why?
|
| Fever | 1 | 1988 | 1616 | 0.000 |
Why?
|
| Stress, Psychological | 1 | 1996 | 4245 | 0.000 |
Why?
|
| Agammaglobulinemia | 1 | 1982 | 167 | 0.000 |
Why?
|
| Pneumonia | 1 | 1992 | 2133 | 0.000 |
Why?
|
| Vincristine | 2 | 1972 | 1039 | 0.000 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 1980 | 156 | 0.000 |
Why?
|
| HIV | 1 | 1987 | 1604 | 0.000 |
Why?
|
| Fluorometry | 2 | 1970 | 106 | 0.000 |
Why?
|
| Ointments | 1 | 1979 | 59 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1993 | 8324 | 0.000 |
Why?
|
| Kidney Neoplasms | 1 | 1976 | 4262 | 0.000 |
Why?
|
| Spectrophotometry | 2 | 1970 | 313 | 0.000 |
Why?
|
| Heart Rate | 2 | 1986 | 4091 | 0.000 |
Why?
|
| Convalescence | 1 | 1978 | 105 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1996 | 9239 | 0.000 |
Why?
|
| Cognition | 1 | 1996 | 6770 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2001 | 41006 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2000 | 40561 | 0.000 |
Why?
|
| Prednisone | 2 | 1972 | 1574 | 0.000 |
Why?
|
| Blood Pressure | 3 | 1986 | 8554 | 0.000 |
Why?
|
| Herpesviridae Infections | 1 | 1979 | 277 | 0.000 |
Why?
|
| Temperature | 1 | 1984 | 2206 | 0.000 |
Why?
|
| Endothelium | 1 | 1979 | 778 | 0.000 |
Why?
|
| Neutralization Tests | 1 | 1978 | 758 | 0.000 |
Why?
|
| Polyethylene Glycols | 1 | 1982 | 1182 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1987 | 5524 | 0.000 |
Why?
|
| Child | 2 | 2001 | 77709 | 0.000 |
Why?
|
| Epinephrine | 1 | 1979 | 792 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2000 | 57776 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 35421 | 0.000 |
Why?
|
| Defective Viruses | 1 | 1975 | 112 | 0.000 |
Why?
|
| Arteriosclerosis | 1 | 1979 | 1092 | 0.000 |
Why?
|
| Dogs | 2 | 1970 | 3912 | 0.000 |
Why?
|
| Virus Cultivation | 1 | 1973 | 92 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1973 | 313 | 0.000 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1973 | 111 | 0.000 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 1972 | 45 | 0.000 |
Why?
|
| Procarbazine | 1 | 1972 | 181 | 0.000 |
Why?
|
| Diploidy | 1 | 1972 | 138 | 0.000 |
Why?
|
| Carbon Isotopes | 1 | 1973 | 467 | 0.000 |
Why?
|
| Cytogenetics | 1 | 1972 | 203 | 0.000 |
Why?
|
| Splenomegaly | 1 | 1972 | 190 | 0.000 |
Why?
|
| Cytosine | 1 | 1973 | 216 | 0.000 |
Why?
|
| Chromosomes | 1 | 1975 | 596 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1973 | 1375 | 0.000 |
Why?
|
| Diplopia | 1 | 1972 | 200 | 0.000 |
Why?
|
| Anuria | 1 | 1970 | 15 | 0.000 |
Why?
|
| Trimethaphan | 1 | 1970 | 13 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1973 | 2255 | 0.000 |
Why?
|
| Lactates | 1 | 1970 | 432 | 0.000 |
Why?
|
| Aneuploidy | 1 | 1972 | 530 | 0.000 |
Why?
|
| Oxygen | 1 | 1980 | 4189 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1985 | 11483 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1978 | 3176 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1973 | 1354 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1975 | 4740 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 1993 | 77449 | 0.000 |
Why?
|
| Head and Neck Neoplasms | 1 | 1972 | 2734 | 0.000 |
Why?
|
| Glucose | 1 | 1970 | 4397 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1972 | 4034 | 0.000 |
Why?
|